TeneoBio Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:TeneoBio Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11094
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:19
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
TeneoBio Inc (TeneoBio), formerly OMT Therapeutics Inc is a biotechnology company. The company develops biologics, human heavy chain antibodies as therapeutics that targets the cancer, autoimmunity, and infectious diseases. Its pre-clinical pipeline portfolio includes antibodies such as multiple myeloma bispecific, lymphoma trispecific, Gp120 (HIV) bispecific and immune checkpoint inhibitors. TeneoBio developed a novel approach by using the NGS and bioinformatics to identify the full antigen specific repertoire of heavy chain antibodies generated by UniRat after immunization. It develops novel drugs for the treatment of multiple myeloma, prostate cancer, immune disorders, multiple myeloma bispecific, lymphoma trispecific, and AIDS. TeneoBio is headquartered in Menlo Park, California, the US.

TeneoBio Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
TeneoBio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
TeneoBio Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
TeneoBio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
TeneoBio Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
TeneoBio Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
TeneoBio Inc, Pharmaceuticals & Healthcare, Deal Details 10
Licensing Agreements 10
Poseida Therapeutics Enters into Licensing Agreement with Teneobio 10
Janssen Biotech Enters into Licensing Agreement with Teneobio 11
TESARO Enters into Research and Licensing Agreement with TeneoBio 12
Poseida Therapeutics Enters into Licensing Agreement with Teneobio for UniDabs 13
TeneoBio Enters into Licensing Agreement with Ligand Pharma 14
TeneoBio Inc – Key Competitors 15
TeneoBio Inc – Key Employees 16
TeneoBio Inc – Locations And Subsidiaries 17
Head Office 17
Recent Developments 18
Product News 18
05/01/2017: Teneobio’s Next Generation T Cell Redirection Antibody Platform for Cancer Biotherapeutics Offers Prospects of Reducing Cytokine Release 18
Appendix 19
Methodology 19
About GlobalData 19
Contact Us 19
Disclaimer 19

List of Tables
TeneoBio Inc, Pharmaceuticals & Healthcare, Key Facts 2
TeneoBio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
TeneoBio Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
TeneoBio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
TeneoBio Inc, Deals By Therapy Area, 2012 to YTD 2018 8
TeneoBio Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Poseida Therapeutics Enters into Licensing Agreement with Teneobio 10
Janssen Biotech Enters into Licensing Agreement with Teneobio 11
TESARO Enters into Research and Licensing Agreement with TeneoBio 12
Poseida Therapeutics Enters into Licensing Agreement with Teneobio for UniDabs 13
TeneoBio Enters into Licensing Agreement with Ligand Pharma 14
TeneoBio Inc, Key Competitors 15
TeneoBio Inc, Key Employees 16

List of Figures
TeneoBio Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
TeneoBio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
TeneoBio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
TeneoBio Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
TeneoBio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
TeneoBio Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
TeneoBio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
TeneoBio Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[TeneoBio Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Polaris Infrastructure Inc (PIF):企業の財務・戦略的SWOT分析
    Summary Polaris Infrastructure Inc (Polaris Infrastructure), formerly Ram Power Corp is a renewable energy company that explores, acquires, operates and develops geothermal energy projects in Latin America. The company owns and operates San Jacinto Tizate Geothermal project, which is located in nort …
  • Medanito SA:石油・ガス:M&Aディール及び事業提携情報
    Summary Medanito SA (Medanito) is an upstream energy company. The company operates in the business of exploration and production of oil and natural gas with participation in the development of unconventional reserves. It operates in the gathering and processing of natural gas liquids (NGL); and gas- …
  • Guangzhou Wondfo Biotech Co Ltd (300482):製薬・医療:M&Aディール及び事業提携情報
    Summary Guangzhou Wondfo Biotech Co Ltd (Wondfo) is a biological company that develops, manufactures and supplies rapid diagnostic reagents and related equipment. Its products include rapid quantitative test, immunofluorescent test system, glucose monitoring system, and raw materials. Wondfo also of …
  • National Australia Bank Private Wealth:企業の戦略・SWOT・財務情報
    National Australia Bank Private Wealth - Strategy, SWOT and Corporate Finance Report Summary National Australia Bank Private Wealth - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT ana …
  • Jupiter Telecommunications Co Ltd:企業の戦略的SWOT分析
    Jupiter Telecommunications Co Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major p …
  • SciClone Pharmaceuticals Inc (SCLN)-製薬・医療分野:企業M&A・提携分析
    Summary SciClone Pharmaceuticals Inc (SciClone) develops and commercializes products for the treatment of cancer, cardiovascular disorders and infectious diseases. The company’s lead product, Zadaxin (thymalfasin), an immunostimulatory agent approved for the treatment of hepatitis B virus (HBV), hep …
  • Flexsteel Industries Inc (FLXS):企業の財務・戦略的SWOT分析
    Flexsteel Industries Inc (FLXS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Centrose LLC:製薬・医療:M&Aディール及び事業提携情報
    Summary Centrose LLC (Centrose) is a precision drug company that develops medicines to target diseased tissues. The company's product pipeline includes EDC1 (Dysadherin), EDC2 (CD147), EDC3 (CD98), EDC5 (CD44), and EDC8 (CD38). Its product EDC1 combines two proteins found in close proximity to treat …
  • Sulzer Ltd (SUN):企業の財務・戦略的SWOT分析
    Sulzer Ltd (SUN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Rafael Pharmaceuticals Inc-製薬・医療分野:企業M&A・提携分析
    Summary Rafael Pharmaceuticals Inc (Rafael Pharmaceuticals), a subsidiary of IDT Corp is a healthcare products provider that offers therapeutics. The company develops drug therapies for the treatment of cancer. It provides altered energy metabolism directed platform for cancer cell energy metabolism …
  • Entreprise Tunisienne d’Activites Petrolieres:企業の戦略的SWOT分析
    Entreprise Tunisienne d'Activites Petrolieres - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors …
  • Cosan S.A. Industria e Comercio (CSAN3)-エネルギー分野:企業M&A・提携分析
    Summary Cosan S.A. Industria e Comercio (Cosan), a subsidiary of Cosan Limited, is an integrated bioenergy company. It invests in diversified industries, including agribusiness, fuel and natural gas distribution, and lubricants. The company distributes lubricants, fuel oil, and piped natural gas; an …
  • ProAxsis Ltd-医療機器分野:企業M&A・提携分析
    Summary ProAxsis Ltd (ProAxsis), formerly ProAx-Sis Ltd, a subsidiary of NetScientific UK Ltd, is a developer of novel, point of care tests for the monitoring of patients with chronic diseases. The company develops proteasetags based point of care tests to offer a visual readout of active proteases …
  • Gordon Ramsay Holdings Limited:企業の戦略・SWOT・財務情報
    Gordon Ramsay Holdings Limited - Strategy, SWOT and Corporate Finance Report Summary Gordon Ramsay Holdings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • BaxterStorey Ltd:企業の戦略・SWOT・財務分析
    BaxterStorey Ltd - Strategy, SWOT and Corporate Finance Report Summary BaxterStorey Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Olon SpA:製薬・医療:M&Aディール及び事業提携情報
    Summary Olon SpA (Olon), formerly Antibioticos SpA, a susbsidiary of P&R S.p.A. is a developer and producer of active pharmaceutical ingredients. The company offers products such as azacitidine, bezafibrate, ibuprofen sodium, acamprosate calcium, acebutolol hydrochloride, acitretin, thalidomide, aba …
  • Hollingsworth & Vose Company:企業の戦略的SWOT分析
    Hollingsworth & Vose Company - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • Becle S.A.B. de C.V. (CUERVO):企業の財務・戦略的SWOT分析
    Becle S.A.B. de C.V. (CUERVO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Pennant International Group plc (PEN):企業の財務・戦略的SWOT分析
    Summary Pennant International Group plc (Pennant) is a technology company that offers information services, training systems, and software services to its customers. The company offers supportability engineering software products, generic training equipment and LSAR software. Pennant generic trainin …
  • Wyndham Destinations, Inc.:企業の戦略・SWOT・財務情報
    Wyndham Destinations, Inc. - Strategy, SWOT and Corporate Finance Report Summary Wyndham Destinations, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆